RAPPORT dwar il-proposta għal regolament tal-Parlament Ewropew u tal-Kunsill dwar iċ-Ċentru Ewropew għall-Monitoraġġ tad-Droga u d-Dipendenza fuq id-Droga

3.4.2006 - (COM(2005)0399 – C6‑0256/2005 – 2005/0166(COD)) - ***I

Kumitat għal-Libertajiet Ċivili, il-Ġustizzja u l-Intern
Rapporteur: Frederika Brepoels

ABBOZZ TA' RIŻOLUZZJONI LEĠIŻLATTIVA TAL-PARLAMENT EWROPEW

dwar il-proposta għal regolament tal-Parlament Ewropew u tal-Kunsill dwar iċ-Ċentru Ewropew għall-Monitoraġġ tad-Droga u d-Dipendenza fuq id-Droga

(COM(2005)0399 – C6‑0256/2005 – 2005/0166(COD))

(Proċedura ta' kodeċiżjoni: l-ewwel qari)

Il-Parlament Ewropew,

–   wara li kkunsidra l-proposta tal-Kummissjoni lill-Parlament Ewropew u lill-Kunsill (COM(2005)0399)[1],

–   wara li kkunsidra l-Artikolu 251(2) u l-Artikolu 152 tat-Trattat KE, skond liema artikoli l-Kummissjoni ppreżentat il-proposta lill-Parlament (C6-0256/2005),

–   wara li kkunsidra l-Artikolu 51 tar-Regoli ta' Proċedura tiegħu,

–   wara li kkunsidra r-rapport tal-Kumitat għal-Libertajiet Ċivili, il-Ġustizzja u l-Intern u l-opinjoni tal-Kumitat għall-Ambjent, is-Saħħa Pubblika u s-Sigurtà ta' l-Ikel (A6‑0124/2006),

1.  Japprova l-proposta tal-Kummissjoni kif emendata;

2.  Jitlob lill-Kummissjoni biex terġa' tirreferi l-proposta lill-Parlament jekk ikollha l-ħsieb li temenda l-proposta b'mod sustanzjali jew li tibdilha b'test ġdid;

3.  Jagħti istruzzjonijiet lill-President tiegħu sabiex jgħaddi l-pożizzjoni tal-Parlament lill-Kunsill u lill-Kummissjoni.

Test propost mill-Kummissjoni	Emendi tal-Parlament
Emenda 1 Premessa 7 a (ġdida)
	(7a) Għandha tkun waħda mill-ħidmiet taċ-Ċentru li jipprovdi informazzjoni dwar l-aħjar prattiki u linji gwida fl-Istati Membri u li jiffaċilita l-iskambju ta' dawn il-prattiki fosthom.
Emenda 2 Premessa 8
(8) Ir-Riżoluzzjoni tal-Kunsill tal-15 ta’ Novembru 2001 dwar l-implimentazzjoni tal-ħames indikaturi epidemoloġiċi dwar id-droga tinkoraġġixxi lill-Istati Membri sabiex jiżguraw, permezz tal-punti fokali nazzjonali, li tkun disponibbli informazzjoni komparabbli dwar il-ħames indikaturi epidemoloġiċi ewlenin.	(8) Ir-Riżoluzzjoni tal-Kunsill tal-15 ta’ Novembru 2001 dwar l-implimentazzjoni tal-ħames indikaturi epidemoloġiċi dwar id-droga tħeġġeġ lill-Istati Membri sabiex jiżguraw, permezz tal-punti fokali nazzjonali, li tkun disponibbli informazzjoni komparabbli dwar il-ħames indikaturi epidemoloġiċi ewlenin. L-implimentazzjoni ta' dawn l-indikaturi mill-Istati Membri hi kundizzjoni bil-quddiem għaċ-Ċentru sabiex iwettaq ix-xogħol tiegħu kif stipulat f'dan ir-Regolament.
Emenda 3 Premessa 9 a (ġdida)
	(9a) Il-mod ta' kif iċ-Ċentru hu organizzat u l-metodi tiegħu ta' ħidma għandhom ikunu konsistenti man-natura oġġettiva tar-riżultati mixtieqa, partikolarment il-paragunabilità u l-kompatibilità ta' sorsi u ta' metodi li għandhom x'jaqsmu ma' l-informazzjoni dwar id-droga.
Ġustifikazzjoni
L-iskop ta' din l-emenda hu li terġa' tiddaħħal premessa li ġiet imħassra fil-proposta tal-Kummissjoni. Sabiex jintlaħaq paragun oġġettiv, l-informazzjoni miġbura miċ-Ċentru trid tkun pargunabbli u kompatibbli.
Emenda 4 Premessa 11
(11) Diġà jeżistu organizzazzjonijiet nazzjonali, Ewropej u internazzjonali u korpi li jfornu din it-tip ta' informazzjoni, u ċ-Ċentru għandu jkun jista' jwettaq id-doveri tiegħu b'kooperazzjoni mill-qrib magħhom.	(11) Diġà jeżistu organizzazzjonijiet u entitajiet nazzjonali, Ewropej u internazzjonali li jfornu din it-tip ta' informazzjoni, u ċ-Ċentru jrid jkun jista' jwettaq id-doveri tiegħu b'kooperazzjoni mill-qrib magħhom.
Emenda 5 Premessa 16
(16) Sabiex ikun żgurat li l-Parlament Ewropew ikun infurmat tajjeb dwar l-istat tal-fenomenu tad-droga fl-Unjoni Ewropea, huwa għandu jkun jista’ jpoġġi domandi lid-Direttur taċ-Ċentru.	(16) Sabiex ikun żgurat li l-Parlament Ewropew ikun infurmat tajjeb dwar l-istat tal-fenomenu tad-droga fl-Unjoni Ewropea, huwa għandu jkollu dritt jagħmel mistoqsijiet lid-Direttur taċ-Ċentru.
Emenda 6 Artikolu 1, paragrafu 2
2. L-għan taċ-Ċentru huwa li jipprovdi, fl-oqsma msemmija fl-Artikolu 3, lill-Komunità u l-Istati Membri tagħha b'informazzjoni oġġettiva, ta' min joqgħod fuqha u kumparabbli fil-livell Ewropew rigward id-droga u l-vizzju tad-droga u l-konsegwenzi tagħhom.	2. L-għan taċ-Ċentru huwa li jipprovdi, fl-oqsma msemmija fl-Artikolu 3, lill-Komunità u l-Istati Membri tagħha b'informazzjoni ta' natura fattwali, oġġettiva, ta' min joqgħod fuqha u kumparabbli fil-livell Ewropew rigward id-droga u l-vizzju tad-droga u l-konsegwenzi tagħhom.
Ġustifikazzjoni
L-informazzjoni pprovduta miċ-Ċentu trid tkun ta' natura fattwali u preċiża, sabiex ikun żgurat li ċ-Ċentru jipprovdi biss assistenza relevanti lil gvernijiet, istituzzjonijiet u organizzazzjonijiet.
Emenda 7 Artikolu 1, paragrafu 3
3. L-informazzjoni statistika, dokumentarja u teknika proċessata jew prodotta hija maħsuba biex tgħin sabiex tipprovdi lill-Komunità u lill-Istati Membri b'viżjoni ġenerali dwar is-sitwazzjoni tad-droga u d-dipendenza fuq id-droga meta, fl-oqsma ta' kompetenza rispettiva tagħhom, jieħdu miżuri jew jiddeċiedu dwar azzjoni. L-element statistiku ta’ din l-informazzjoni għandu jkun żviluppat, f’kollaborazzjoni ma’ l-awtoritajiet statistiċi rilevanti, bl-użu meta jkun meħtieġ tal-Programm Statistiku tal-Komunità sabiex tkun promossa s-sinerġija u evitata d-duplikazzjoni.	3. L-informazzjoni statistika, dokumentarja u teknika proċessata jew prodotta hija maħsuba biex tgħin sabiex tipprovdi lill-Komunità u lill-Istati Membri b'viżjoni ġenerali dwar is-sitwazzjoni tad-droga u d-dipendenza fuq id-droga meta, fl-oqsma ta' kompetenza rispettiva tagħhom, jieħdu miżuri jew jiddeċiedu dwar azzjoni. L-element statistiku ta’ din l-informazzjoni għandu jkun żviluppat, f’kollaborazzjoni ma’ l-awtoritajiet statistiċi rilevanti, bl-użu meta jkun meħtieġ tal-Programm Statistiku tal-Komunità sabiex tkun promossa s-sinerġija u evitata d-duplikazzjoni. Għandha tittieħed kunsiderazzjoni għal aktar dejta tal-WHO u tan-NU disponibbli madwar id-dinja.
Ġustifikazzjoni
Sabiex tkun evitata dupplikazzjoni.
Emenda 8 Artikolu 1, paragrafu 5
5. Iċ-Ċentru m'għandux jiġbor dettalji li jagħmluha possibli li jkunu identifikati individwi jew gruppi żgħar ta' individwi. Għandu jibqa' lura milli jittrażmetti informazzjoni li għandha x'taqsam ma' każi speċifiċi msemmija b'isimhom.	5. Iċ-Ċentru m'għandux jiġbor dettalji li jagħmluha possibbli li jkunu identifikati individwi jew gruppi żgħar ta' individwi. Għandu jibqa' lura milli jittrażmetti informazzjoni li għandha x'taqsam ma' każi speċifiċi msemmija b'isimhom sakemm ma jkunux saru reati kriminali.
Ġustifikazzjoni
Ma jkunx aċċettabbli li informazzjoni ta' importanza kruċjali għal investigazzjoni ta' reat kriminali tkun disponibbli, imma tiġi miżmuma.
Emenda 9 Artikolu 2, punt (a) (i)
(i) jiġbor, jirreġistra u janalizza informazzjoni, inklużi dettalji li jirriżultaw minn riċerka, ikkomunikati minn Stati Membri kif ukoll li joħorġu mill-Komunità, sorsi nazzjonali mhux governattivi u organizzazzjonijiet kompetenti internazzjonali; dan x-xogħol ta’ ġbir, reġistrazzjoni u analiżi għandu jkopri wkoll data dwar xejriet li jkunu qed jiżviluppaw fl-użu tad-drogi flimkien, inkluż l-użu flimkien ta' sustanzi psikoattivi legali u illegali;	(i) jiġbor, jirreġistra u janalizza informazzjoni, inklużi dettalji li jirriżultaw minn riċerka, ikkomunikati minn Stati Membri kif ukoll li joħorġu mill-Komunità, sorsi nazzjonali mhux governattivi u organizzazzjonijiet kompetenti internazzjonali, inkuża l-Europol; jipprovdi informazzjoni dwar l-aħjar prattiki fl-Istati Membri u jiffaċilita l-iskambju ta' dawn il-prattiki fosthom; dan x-xogħol ta’ ġbir, ta' reġistrazzjoni, ta' informazzjoni u ta' analiżi għandu jkopri wkoll dejta dwar xejriet li jkunu qed jiżviluppaw fl-użu tad-drogi flimkien, inkluż l-użu flimkien ta' sustanzi psikoattivi legali u illegali;
Ġustifikazzjoni
Waħda mill-ħidmiet ta' l-Aġenzija għandha ovvjament tikkonsisti fit-trawwim ta' l-iskambju ta' l-aħjar prattiki.
Emenda 10 Artikolu 2, punt (a) (v)
(v) jiffaċilita l-iskambju ta' l-informazzjoni bejn dawk li jieħdu d-deċiżjonijiet, riċerkaturi, speċjalisti u dawk involuti fil-ġlieda kontra d-droga fl-organizzazzjonijiet governattivi u mhux governattivi;	(v) jiffaċilita l-iskambju ta' l-informazzjoni bejn dawk li jieħdu d-deċiżjonijiet, riċerkaturi, speċjalisti u dawk involuti fi kwistjonijiet li għandhom x'jaqsmu ma' droga fl-organizzazzjonijiet governattivi u mhux governattivi;
Emenda 11 Artikolu 2, punt (d) (ii a) (ġdid)
	(iia) jikkopera b'mod attiv ma' l-Europol sabiex jakkwista effiċjenza massima fil-monitoraġġ tal-problema tad-drogi;
Ġustifikazzjoni
Tqassim ta' informazzjoni dwar l-użu tad-droga u kriminalità relatata mad-droga jkun ta' benefiċċju kemm għall-EMCDDA kif ukoll għall-Europol.
Emenda 12 Artikolu 2, punt (d a) (ġdid)
	(da) Obbligazzjonijiet ta' l-informazzjoni Iċ-Ċentru għandu jkun obbligat, jekk jagħraf żviluppi ġodda u tendenzi ta' bidla, li jinforma l-awtoritajiet kompetenti ta' l-Istati Membri.
Ġustifikazzjoni
Irid ikun ċar li ċ-Ċentru jrid jopera proattivament u jidentifika perikli fuq inizjattiva tiegħu.
Emenda 13 Artikolu 5, paragrafu 2, punt (a)
(a) Il-punti fokali nazzjonali għandhom jiffurmaw punt ta’ kuntatt bejn il-pajjiżi li jkunu qed jipparteċipaw u ċ-Ċentru. Huma għandhom jikkontribwixxu għat-twaqqif ta’ indikaturi u data prinċipali, inklużi linji gwida għall-implimentazzoni tagħhom bil-ħsieb li tinkiseb informazzjoni affidabbli u komparabbli fuq il-livell ta’ l-Unjoni Ewropea. Huma għandhom jiġbru u janalizzaw fuq livell nazzjonali l-informazzjoni kollha rilevanti dwar id-droga u d-dipendenza fuq id-droga, kif ukoll dwar policies u soluzzjonijiet applikati. B’mod partikolari, huma għandhom jipprovdu data għall-ħames indikaturi epidemoloġiċi speċifikati miċ-Ċentru.	(a) Il-punti fokali nazzjonali għandhom jiffurmaw punt ta’ kuntatt bejn il-pajjiżi li jkunu qed jipparteċipaw u ċ-Ċentru. Huma għandhom jikkontribwixxu għat-twaqqif ta’ indikaturi u data prinċipali, inklużi linji gwida għall-implimentazzjoni tagħhom bil-ħsieb li tinkiseb informazzjoni affidabbli u komparabbli fuq il-livell ta’ l-Unjoni Ewropea. Huma għandhom jiġbru u janalizzaw b'mod oġġettiv fuq livell nazzjonali, ilaqqgħu l-esperjenzi kollha minn setturi differenti - saħħa, ġustizzja, infurzar tal-liġi, b'koperazzjoni ma' esperti u organizzazzjonijiet nazzjonali attivi fil-qasam tal-politika tad-droga, l-informazzjoni kollha rilevanti dwar id-droga u d-dipendenza fuq id-droga, kif ukoll dwar politiki u soluzzjonijiet applikati. B’mod partikolari, huma għandhom jipprovdu dejta għall-ħames indikaturi epidemoloġiċi speċifikati miċ-Ċentru.
Ġustifikazzjoni
Il-punti li wieħed għandu jiffoka fuqhom għandhom jisfruttaw l-għarfien ta' l-NGOs u ta' esperti attivi fil-qasam.
Emenda 14 Artikolu 6, paragrafu -1 u -1 a (ġdid)
	Dejta dwar drogi u dipendenza fuq id-droga pprovduta lil jew miċ-Ċentru tista' tiġi ppubblikata sakemm tkun konformi mar-regoli Komunitarji u nazzjonali dwar id-disseminazzjoni u l-kunfidenzjalità ta' l-informazzjoni. Dejta personali ma tistax tiġi ppubblikata jew tkun disponibbli għall-pubbliku.
	L-Istati Membri u ċ-ċentri speċjalizzati m'għandhomx ikunu obbligati li jipprovdu informazzjoni klassifikata bħala kunfidenzjali skond il-liġi nazzjonali tagħhom.

Ġustifikazzjoni

L-iskop ta' din l-emenda hu li jerggħu jiddaħħlu żewġ paragrafi li kienu tneħħew mill-proposta tal-Kummissjoni, u li tinbidel l-ordni tal-paragrafi.

Emenda 15 Artikolu 9, paragrafu 4
4. Il-bord tal-ġestjoni għandu jadotta programm ta' ħidma għal tliet snin fuq il-bażi ta' abbozz preżentat mid-Direttur taċ-Ċentru, wara li jikkonsulta lill-Kumitat Xjentifiku u jitlob l-opinjonijiet tal-Kummissjoni u għandu jgħaddih lill-Parlament Ewropew, lill-Kunsill u lill-Kummissjoni.	4. Il-bord tal-ġestjoni għandu jadotta programm ta' ħidma għal tliet snin fuq il-bażi ta' abbozz preżentat mid-Direttur taċ-Ċentru, wara li jikkonsulta lill-Kumitat Xjentifiku u jitlob l-opinjonijiet tal-Kummissjoni u tal-Parlament Ewropew, u għandu jgħaddih lill-Parlament Ewropew, lill-Kunsill u lill-Kummissjoni.
Ġustifikazzjoni Il-Parlament Ewropew għandu jiġi kkonsultat qabel l-adozzjoni tal-programm ta' ħidma.
Emenda 16 Artikolu 9, paragrafu 6
6. Fil-każ fejn il-Kummissjoni tesprimi n-nuqqas ta’ qbil tagħha mal-programm ta’ ħidma ta’ tliet snin jew dak annwali, dawn il-programmi għandhom ikunu adottati mill-Bord tal-ġestjoni b'maġġoranza ta' 4/5.	6. Fejn il-Kummissjoni tesprimi n-nuqqas ta’ qbil tagħha mal-programm ta’ ħidma ta’ tliet snin jew dak annwali, dawn il-programmi għandhom ikunu adottati mill-Bord tal-ġestjoni b'maġġoranza ta' 3/4.
Ġustifikazzjoni
Il-maġġoranza li hemm bżonn tinbidel minn 4/5 għal 3/4 sabiex tiffaċilita t-teħid ta' deċiżjonijiet meta il-Kummissjoni ma taqbilx ma' l-abbozz tal-programmi ta' ħidma.
Emenda 17 Artikolu 10
1. Il-Bord tal-Ġestjoni għandu jkun megħjun minn Kumitat Eżekuttiv. Il-Kumitat Eżekuttiv għandu jikkonsisti mill-President u l-Viċi-President tal-Bord tal-Ġestjoni u żewġ rappreżentanti tal-Kummissjoni. Id-Direttur għandu jieħu sehem fil-laqgħat tiegħu, mingħajr id-dritt tal-vot.	1. Il-Bord tal-Ġestjoni għandu jkun megħjun minn Kumitat Eżekuttiv. Il-Kumitat Eżekuttiv għandu jikkonsisti mill-President u l-Viċi-President tal-Bord tal-Ġestjoni, żewġ membri oħra mill-Bord tal-Ġestjoni li jirrappreżentaw l-Istati Membri u maħtura mill-Bord tal-Ġestjoni u żewġ rappreżentanti tal-Kummissjoni. Id-Direttur għandu jieħu sehem fil-laqgħat tiegħu.
2. Il-Kumitat Eżekuttiv għandu jiltaqa' mill-anqas darbtejn fis-sena u kulmeta jkun meħtieġ li jkunu ppreparati deċiżjonijiet tal-Bord tal-Ġestjoni u li tingħata għajnuna jew pariri lid-Direttur. Huwa għandu jiddeċiedi għall-Bord tal-Ġestjoni dwar materji previsti fir-regolament finanzjarju ta’ l-EMCDDA li mhumiex riżervati għall-Bord tal-Ġestjoni b’dan ir-Regolament. Huwa għandu jadotta d-deċiżjonijiet b’maġġoranza sempliċi.	2. Il-Kumitat Eżekuttiv għandu jiltaqa' mill-anqas darbtejn fis-sena u kulmeta jkun meħtieġ li jkunu ppreparati deċiżjonijiet tal-Bord tal-Ġestjoni u li tingħata għajnuna jew pariri lid-Direttur. Huwa għandu jiddeċiedi għall-Bord tal-Ġestjoni dwar materji previsti fir-regolament finanzjarju ta’ l-EMCDDA li mhumiex riżervati għall-Bord tal-Ġestjoni b’dan ir-Regolament. Deċiżjonijiet għandhom jiġu adottati billi jintlaħaq kunsens.
Emenda 18 Artikolu 11, paragrafu 1
1. Iċ-Ċentru għandu jkun immexxi minn Direttur maħtur mill-bord tal-ġestjoni fuq proposta tal-Kummissjoni għal perjodu ta' ħames snin, fuq proposta tal-Kummissjoni u wara evalwazzjoni, jista’ jiġġedded darba għal perjodu ta’ mhux aktar minn ħames snin	1. Iċ-Ċentru għandu jkun immexxi minn Direttur maħtur mill-Bord Maniġerjali fuq proposta tal-Kummissjoni u wara l-approvazzjoni mill-Parlament Ewropew għal perjodu ta' ħames snin. Il-proposta għandha tikkonsisti minn lista ta' l-aħjar kandidati magħżula mill-Kummissjoni wara kompetizzjoni miftuħa. Fuq proposta tal-Kummissjoni u wara evalazzjoni, il-mandat tad-Direttur jista’ jiġġedded darba waħda għal perijodu li ma jaqbiżx il-ħames snin.
Fl-evalwazzjoni l-Kummissjoni għandha tevalwa b’mod partikolari:	Fil-qafas ta' l-evalwazzjoni, il-Bord Maniġerjali għandu jevalwa b'mod partikolari:
– Ir-riżultati miksuba matul l-ewwel mandat u l-mod kif ikunu nkisbu;	– ir-riżultati miksuba matul l-ewwel mandat u l-mod kif ikunu nkisbu;
– Id-dmirijiet u l-ħtiġijiet taċ-ċentru fis-snin li jkunu ġejjin	– id-dmirijiet u l-ħtiġijiet taċ-ċentru fis-snin li jkunu ġejjin.
	L-evalwazzjoni għandha titressaq mingħajr dewmien lill-Kummissjoni u lill-Parlament Ewropew.
Ġustifikazzjoni
L-għażla finali għandha ssir mill-Bord Maniġerjali. Din il-formulazzjoni intużat riċenti f'diversi Regolamenti li jistabbilixxu aġenziji Komunitarji (l-EMEA, iċ-Ċentru għall-Prevenzjoni u għall-Kontroll tal-Mard). Il-proċedura ta' applikazzjoni u għażla għandha tkun trasparenti kemm jista' jkun sabiex tiġbed l-attenzjoni ta' kandidati potenzjali. Il-Bord Maniġerjali, bħala l-awtorità maħtura għandu jevalwa x-xogħol tad-Direttur. Id-deċiżjoni sabiex jiġi estiż il-mandat tad-Direttur għandha tittieħed biss wara dan, jekk ikun xieraq. Peress li l-evalwazzjoni tikkonċerna uffiċjal pubbliku u aġenzija Komunitarja, hu importanti li l-evalwazzjoni tkun disponibbli għall-Kummissjoni u l-Parlament Ewropew.
Emenda 19 Artikolu 11, paragrafu 2
2. Meta jingħata l-ewwel mandat minn massimu ta' tnejn, il-kandidat innominat mill-Bord tal-Ġestjoni għall-kariga ta' Direttur jista' jkun mistieden bla dewmien biex jagħmel stqarrija quddiem il-Parlament Ewropew u jwieġeb mistoqsijiet li jitpoġġew minn membri ta' dik l-istituzzjoni.	2. Meta jingħata l-ewwel mandat minn massimu ta' tnejn, il-kandidat innominat mill-Bord Maniġerjali għall-kariga ta' Direttur għandu jkun mistieden bla dewmien biex jagħmel stqarrija quddiem il-Parlament Ewropew u jwieġeb mistoqsijiet li jitpoġġew minn membri ta' dik l-istituzzjoni.
Ġustifikazzjoni
Bħall-każ ta' agenziji oħra deċentralizzati, għandha tkun ħaġa obbligatorja li d-Direttur nominat jersaq quddiem il-Parlament qabel l-ħatra finali.
Emenda 20 Artikolu 12, titolu
Smigħ tad-Direttur quddiem il-Parlament Ewropew	Smigħ tad-Direttur u taċ-'Chairperson' tal-Bord Maniġerjali quddiem il-Parlament Ewropew
Ġustifikazzjoni
Il-ħila u l-għarfien taċ-'Chairperson' tal-Bord Maniġerjali jista' jkun ta' interess kbir għall-PE.
Emenda 21 Artikolu 12
Kull sena, id-Direttur għandu jippreżenta lill-Parlament Ewropew ir-rapport ġenerali dwar l-attivitajiet taċ-Ċentru. Il-Parlament Ewropew jista’ wkoll jitlob smigħ mad-Direttur dwar kull suġġett relatat ma' l-attivitajiet taċ-Ċentru.	Kull sena, id-Direttur għandu jippreżenta lill-Parlament Ewropew ir-rapport ġenerali dwar l-attivitajiet taċ-Ċentru. Il-Parlament Ewropew jista’ wkoll jitlob smigħ mad-Direttur u maċ-'Chairperson' tal-Bord Maniġerjali dwar kull suġġett relatat ma' l-attivitajiet taċ-Ċentru.
Ġustifikazzjoni
Il-ħila u l-għarfien taċ-'Chairperson' tal-Bord Maniġerjali jista' jkun ta' interess kbir għall-PE.
Emenda 22 Artikolu 13, paragrafu 2, subparagrafu 1
2. Il-Bord tal-Ġestjoni għandu jappunta membru għal kull Stat Membru fuq il-Kumitat Xjentifiku fuq il-bażi ta’ proposti mill-Istati Membri dwar individwi magħżula fuq il-bażi ta’ l-esperjenza u l-eċċellenza xjentifika tagħhom fil-qasam tad-droga u d-dipendenza fuq id-droga, u bl-għoti tal-piż xieraq lill-bżonn li l-Kumitat ikun multidixxiplinari fin-natura tiegħu u jkopri l-oqsma xjentifiċi kollha marbuta mal-problemi tad-droga u d-dipendenza fuq id-droga. Dawn l-oqsma jinkludu lil dawn li ġejjin, imma m’humiex limitati għalihom biss: Ir-Riċerka Bijomedika, in-Newroxjenza, il-Kriminoloġija, ix-Xjenza Edukattiva, l-Epidemjoloġija,l- Ekonomija, ix-Xjenza Forensika, il-Liġi, l-Evalwazzjoni u l-Analiżi tal-Politika, ix-Xjenza Politika, l-Evalwazzjoni/Riċerka tal-Prevenzjoni, il-Psikjatrija tad-Dipendenza, il-Psikoloġija, il-Psikofarmakoloġija, is-Saħħa Pubblika, ir-Riċerka Kwalitattiva, il-ħidma Soċjali, l-Istatistika, is-Soċjoloġija, ir-Riċerka ta’ l-Istħarriġ, it-Tossikoloġija, u l-Evalwazzjoni/ir-Riċerka tat-Trattament.	2. Il-Kumitat Xjentifiku għandu jikkonsisti minn ta' l-aktar ħmistax-il xjentist magħrufa sew maħtura fuq il-bażi ta’ l-eċċellenza xjentifika tagħhom u l-indipendenza tagħhom mill-Bord Maniġerjali, wara pubblikazzjoni għal sejħa ta' espressjoni ta' interess fil-Ġurnal Uffiċjali ta' l-Unjoni Ewropea. Il-proċedura ta' l-għażla għandha tiżgura li l-oqsma ta' speċjalizzazzjoni tal-membri tal-Kumitat Xjentifiku jkopru l-oqsma xjentifiċi l-aktar relevanti marbuta mal-problemi tad-droga u d-dipendenza fuq id-droga.
Ġustifikazzjoni
Kumitat xjentifiku b'rappreżentant minn kull Stat Membru m'huwiex sinjal ta' tmexxija tajba. Sistema b'numru limitat ta' esperti, maħtura wara kompetizzjoni miftuħa tiżgura l-indipendenza u l-operat effiċjenti tal-kumitat.
Emenda 23 Artikolu 13, paragrafu 2, subparagrafu 2 a (ġdid)
	Il-Kumitat Xjentifiku għandu jikkonsidra l-pożizzjonijiet differenti espressi f'opinjonijiet ta' esperti nazzjonali, jekk disponibbli, qabel ma tiġi finalizzata deċiżjoni.
Emenda 24 Artikolu 13, paragrafu 2, subparagrafu 3
Il-bord tal-Ġestjoni għandu japprova, minn fost il-persuni proposti mill-Istati Membri, grupp ta’ esperti li minnhom mhux aktar minn ħamsa jistgħu jintgħażlu minn żmien għal żmien mid-Direttur li jkun qed jaġixxi fuq parir tal-President tal-Kumitat Xjentifiku, sabiex iservu fuq il-Kumitat Xjentifiku estiż kif stabbilit fl-Artikolu 6.2 tad-Deċiżjoni tal-Kunsill 2005/387/JHA ta’ l-10 ta’ Mejju 2005 dwar l-iskambju ta’ l-informazzjoni, l-evalwazzjoni tar-riskju u l-kontroll ta’ sustanzi psikoattivi ġodda.	imħassar
Emenda 25 Artikolu 20, paragrafu 2
Din il-kooperazzjoni għandha tkun ibbażata fuq ftehimiet ta' ħidma konklużi ma' l-awtoritajiet u organizzazzjonijiet imsemmija. Dawn l-arranġamenti għandhom jiġu adottati mill-Bord tal-Ġestjoni fuq il-bażi ta’ l-abbozz preżentat mid-Direttur u wara li l-Kummissjoni tkun tat l-opinjoni tagħha. Fejn il-Kummissjoni tesprimi nuqqas ta’ qbil ma’ dawn l-arranġamenti, il-Bord tal-Ġestjoni għandu jadottahom b’maġġoranza ta’ 4/5.	Din il-kooperazzjoni għandha tkun ibbażata fuq ftehimiet ta' ħidma konklużi ma' l-awtoritajiet u organizzazzjonijiet imsemmija. Dawn l-arranġamenti għandhom jiġu adottati mill-Bord Maniġerjali fuq il-bażi ta’ l-abbozz preżentat mid-Direttur u wara li l-Kummissjoni tkun tat l-opinjoni tagħha. Fejn il-Kummissjoni tesprimi nuqqas ta’ qbil ma’ dawn l-arranġamenti, il-Bord Maniġerjali għandu jadottahom b’maġġoranza ta’ 3/4.
Ġustifikazzjoni
Nistgħu nirreferu għall-ġustifikazzjoni li tikkonċerna l-emenda 6.
Emenda 26 Artikolu 23, paragrafu 2
F’dak il-kuntest, il-Kummissjoni għandha, jekk ikun xieraq, tippreżenta proposta għar-reviżjoni tad-dispożizzjonijiet ta’ dan ir-Regolament fid-dawl ta’ l-iżviluppi dwar l-aġenziji regolatorji, f'konformità mal-proċedura stabbilita fl-artikolu 251 tat-Trattat. Il-Parlament Ewropew u l-Kunsill għandhom jeżaminaw din il-proposta u b’mod partikolari jikkunsidraw jekk il-kompożizzjoni tal-Bord tal-Ġestjoni jkollhiex bżonn tkun reveduta f’konformità mal-qafas ġenerali li għandu jkun adottat mill-aġenziji regolatorji Ewropej.	F’dak il-kuntest, il-Kummissjoni għandha, jekk ikun xieraq, tippreżenta proposta għar-reviżjoni tad-dispożizzjonijiet ta’ dan ir-Regolament fid-dawl ta’ l-iżviluppi dwar l-aġenziji regolatorji, f'konformità mal-proċedura stabbilita fl-Artikolu 251 tat-Trattat.
Ġustifikazzjoni
M'hemmx għalfejn li tissemma b'mod espliċitu l-kompożizzjoni tal-Bord Maniġerjali fil-kuntest ta' reviżjoni tad-dispożizzjonijiet tar-Regolament.
Emenda 27 Anness I, sezzjoni A, punt 2
(2) il-monitoraġġ tas-soluzzjonijiet applikati għall-problemi relatati mad-droga;	(2) il-monitoraġġ tas-soluzzjonijiet applikati għall-problemi relatati mad-droga; jipprovdi informazzjoni dwar l-aħjar prattiki fl-Istati Membri u jiffaċilita l-iskambju ta' dawn il-prattiki fosthom;
Ġustifikazzjoni
Waħda mill-ħidmiet ta' l-Aġenzija għandha ovvjament tikkonsisti fit-trawwim ta' l-iskambju ta' l-aħjar prattiki.

• [1]  Għadha mhix ippubblikata fil-ĠU.

NOTA SPJEGATTIVA

The proposal for a revision of Council Regulation (EEC) No 302/93 on the establishment of a European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) already has a long history.

Legal aspects of this revision have been debated since the end of 2003, when the Commission submitted an initial proposal for a revision of Council Regulation (EEC) No 302/93. The legal basis chosen at that time was Article 308 of the Treaty. Accordingly, the European Parliament had to be consulted, and delivered an opinion in April 2004 (COD 2003/0311).

After discussions within the Horizontal Drugs Group - the relevant working group of the Council - it was decided to alter the legal basis of the proposal to Article 152 in the Health Chapter. The amendment of the legal basis also entails a change of procedure, as Article 152 requires codecision.

An opinion from the European Parliament's Legal Service indicated that problems might arise if any further work were to be done on the original proposal. The Commission therefore submitted a new proposal, involving the European Parliament under codecision. The present proposal for revision cancels and replaces the former Commission proposal, which the Commission has withdrawn as part of the 'better regulation' exercise.

The subject of the new Commission proposal is consolidation of three previous amendments to the establishing regulation, an increase in the role of the Centre and its adaptation to the new reality of Europe after enlargement.

In future, the Centre will accordingly devote more attention to new trends in drug use, such as the combination of licit and illicit psychoactive substances. The proposal is also designed to adapt the operation of the Centre's bodies in order to take account of enlargement and the everyday practice of the European Union.

The rapporteur's position

The rapporteur can largely endorse the proposal. In its latest form, it already takes account of a number of the European Parliament's ideas and suggestions as set out in the first report (COD 2003/0311). These include the representation of Parliament on the Centre's Management Board and attention for multiple drug use, such as combined use of licit and illicit psychoactive substances. A number of other proposals by Parliament have not been incorporated.

The rapporteur supports the call for more objective and comparable data. At present, not enough data are available from certain Member States, or they are hardly comparable, which hampers general monitoring of the European drugs situation. The rapporteur therefore proposes reinstating a provision from the old regulation as Recital 9a (new).

The rapporteur considers that, in order for information to be gathered efficiently, decision-making needs to be streamlined and to take place in a transparent organisational framework. She therefore supports the inclusion in the EMCDDA Regulation of provisions concerning the Executive Committee, and likewise endorses the regular evaluation of the Centre's work and of the Reitox network and the six-yearly external evaluations: all these changes will promote the efficiency and operation of the Centre.

In order to make it possible for the Executive Committee to operate efficiently it seems appropriate, in addition to the chairman and vice-chairman, to appoint two representatives of the Council and two of the Commission, who must always take decisions by consensus.

The rapporteur feels that it is desirable that, in addition to the Director of the Centre, it should be possible for Parliament to hear the Chairperson of the Management Board.

The Management Board and the Director of the Centre are assisted by a Scientific Committee whose task is to deliver an opinion on any scientific matter concerning the Centre's activities. The rapporteur considers that the Member States are already sufficiently represented on the Management Board and takes the view, partly for that reason but more particularly because this body must be able to work independently, that the Scientific Committee should not have more than 15 members, who should be selected on the basis of their expertise, by means of an open procedure.

Only in the context of the Council Decision of 10 May 2005 on information exchange, risk assessment and control of new psychoactive substances may the Scientific Committee be enlarged to include experts from the Commission, Europol and the EMEA, as well as experts from scientific fields which are insufficiently represented, if at all. Limiting the number of members of the Committee seems to be the only correct way of facilitating efficient organisation and decision-making.

As the Centre's main task is to collect and disseminate information about drugs and drug use, providing information on best practices for tackling the drugs problem and facilitating exchanges of such practices would contribute to the policies of the Member States.

In addition, cooperation between national focal points and organisations active in the field of drugs could make it possible to keep abreast of the European drugs situation quickly and appropriately and enable Member States to respond more effectively to new developments and phenomena relating to drugs and drug use.

OPINJONI TAL-KUMITAT GĦALL-AMBJENT, IS-SAĦĦA PUBBLIKA U S-SIKUREZZA TA' L-IKEL (23.2.2006)

for the Committee on Civil Liberties, Justice and Home Affairs

on the proposal for a regulation of the European Parliament and of the Council on the European Monitoring Centre for Drugs and Drug Addiction
(COM(2005)0399 – C6‑0256/2005 – 2005/0166(COD))

Draftsman: Jiří Maštálka

SHORT JUSTIFICATION

The European Monitoring Centre for Drugs and Drug Addiction was set up by means of Council Regulation (EEC) No 302/93 of 8 February 1993 establishing a European Monitoring Centre for Drugs and Drug Addiction for the purpose of providing the Community and its Member States with objective, reliable and comparable information concerning drugs and drug addiction. In 2003 the Commission submitted a new draft version of that Regulation (COM(2003)0808). Article 308 was selected as the legal basis (as it had been in the case of the original Regulation). The European Parliament was consulted in respect of the draft, although after several months of discussion within the relevant Council working party it was decided that the legal basis would be changed to Article 152, which provides for the codecision procedure. Hence the Commission decided to submit this new revised proposal (COM(2005)0399) so that Parliament could be properly consulted on the matter.

The purpose of the proposal is to 'beef up' the Centre, in particular in order to enable new trends in drug use to be taken into consideration (including the combination of legally permitted and legally banned psychoactive substances) and in order to enable the Centre to adapt to new circumstances following the enlargement of the EU. The proposal should also eliminate the number of ambiguities which were detected after the original Council regulation came into force.

However, in order to ensure that the Centre genuinely operates effectively, some of the provisions contained in the proposal need to be amended in some way. The Centre should not be concerned solely with gathering, analysing and processing data relating to drug issues; rather, it should also be concerned with the systematic evaluation of drug policies (at both EU and Member-State level) and of trends in drug consumption. That would make it easier for the Member States to learn from one another and to exchange experiences in their efforts to combat drug addiction.

A further requirement is that there should be more intensive cooperation between the Centre and non-EU countries, at least in terms of the systematic gathering and analysis of data relating to drug issues, not least in view of the fact that most drugs enter the European Union from non-EU (frequently neighbouring) countries.

The Centre must also devise common criteria and standard data-collection methods to be used by all the parties involved, since that is the only way of ensuring that data relating to drug issues are objective, reliable and above all comparable. Furthermore, the exchange of information between the Centre and Europol concerning drugs and crimes committed in connection with drug use would be beneficial to both parties.

The European Parliament should be more involved in the Centre's activities and should be properly informed regarding its work. Hence when the Centre's three-year work programme is being drawn up, not only the Commission's opinion should be taken into consideration - the European Parliament should be asked for its opinion, too. Parliament should also have one representative on the Executive Committee (an independent expert designated by Parliament).

In order to ensure that the Commission does not have excessive influence over the Centre's work, a mere ¾ majority should be sufficient for the Management Board to adopt important decisions (concerning, for example, the Centre's annual and three-year programme) in cases where the Commission expresses its disagreement.

The Director of the Centre should be nominated in the same way as the directors of other Community bodies. Hence he or she should be nominated by the Executive Committee from a list of candidates proposed by the Commission after a public competition and an invitation to take part therein have been announced in the Official Journal and in one major daily newspaper in each Member State. This method of nominating a director is also more transparent and a public competition would attract a greater number of potential candidates.

The Centre should expand its remit to include the monitoring of psychomodulation substances. If they are abused they cause serious, long-lasting and frequently irreversible damage to health. In the future the Centre should also cover the problems of alcohol and tobacco abuse, since there are close parallels between the problems associated with drug abuse and those associated with alcohol and tobacco abuse. In the case of alcohol and tobacco consumers there is a significantly increased relative risk of drug addiction and people frequently switch from alcohol and tobacco to drugs, or vice versa.

AMENDMENTS

The Committee on the Environment, Public Health and Food Safety calls on the Committee on Civil Liberties, Justice and Home Affairs, as the committee responsible, to incorporate the following amendments in its report:

Text proposed by the Commission[1]	Amendments by Parliament
Amendment 1 Recital 7a (new)
	(7a) Account should also be taken of illicit and inappropriate use of psychomodulation substances, which can have serious consequences on physical and mental health.
Amendment 2 Recital 7 b (new)
	(7b) The Centre should also be entrusted with the task of providing information and evaluating different drug policies in Member States in order to facilitate the dissemination and exchange of best practice.
Justification
Member States should learn from each other's experience on combating drug abuse. The Centre could facilitate this by evaluating the impact of different policies.
Amendment 3 Recital 9
(9) It is desirable for the Commission to be able to entrust the EMCDDA directly with the implementation of Community structural assistance projects relating to drug information systems in non-Community countries such as the candidate countries or the countries of the western Balkans which have been authorised by the European Council to participate in Community programmes and agencies.	(9) It is desirable for the Commission to be able to entrust the EMCDDA directly with the implementation of Community structural assistance projects relating to drug information systems in non-Community European countries such as the candidate countries or the countries of the western Balkans which have been authorised by the European Council to participate in Community programmes and agencies.
Justification
Structural assistance projects should continue to be confined to the candidate countries and the countries of the western Balkans.
Amendment 4 Recital 11
(11) There already exist national, European and international organizations and bodies supplying information of this kind, and the Centre should be able to carry out its tasks in close cooperation with them.	(11) There already exist national, European and international organizations and bodies supplying information of this kind, and the Centre must be able to carry out its tasks in close cooperation with them.
Amendment 5 Recital 16
(16) In order to ensure that the European Parliament is well informed of the state of the drugs phenomenon in the European Union, it must be able to question the Centre's Director.	(16) In order to ensure that the European Parliament is well informed of the state of the drugs phenomenon in the European Union, it must have the right to question the Centre's Director.
Amendment 6 Recital 18
(18) An external evaluation of the EMCDDA's work should be conducted on a regular basis, and this Regulation should be adapted accordingly, if needed.	(18) An external evaluation of the EMCDDA's work should be conducted every three years, and this Regulation should be adapted accordingly, if needed.
Justification
The work of the EMCDDA will be based on three-year work programmes (see Article 9, paragraph 4). It would be logical to carry out an external evaluation during the last year of each period in order to have input for the preparations for the new programme.
Amendment 7 Article 1, paragraph 2
2. The Centre's objective is to provide, in the areas referred to in Article 3, the Community and its Member States with objective, reliable and comparable information at European level concerning drugs and drug addiction and their consequences.	2. The Centre's objective is to provide, in the areas referred to in Article 3, the Community and its Member States with factual, objective, reliable and comparable information at European level concerning drugs and drug addiction and their consequences.
Justification
The information supplied by the centre must be factual and to the point, so as to ensure that the centre provides only relevant assistance to governments, institutions and organisations.
Amendment 8 Article 1, paragraph 3
3. The statistical, documentary and technical information processed or produced is intended to help provide the Community and the Member States with an overall view of the drug and drug addiction situation when, in their respective areas of competence, they take measures or decide on action. The statistical element of this information shall be developed, in collaboration with the relevant statistical authorities, using as necessary the Community Statistical Programme to promote synergy and avoid duplication.	3. The statistical, documentary and technical information processed or produced is intended to help provide the Community and the Member States with an overall view of the drug and drug addiction situation when, in their respective areas of competence, they take measures or decide on action. The statistical element of this information shall be developed, in collaboration with the relevant statistical authorities, using as necessary the Community Statistical Programme to promote synergy and avoid duplication. Account shall be taken of further WHO and UN data available worldwide.
Justification
To avoid duplication.
Amendment 9 Article 1, paragraph 5
5. The Centre shall not collect any data making it possible to identify individuals or small groups of individuals. It shall refrain from any transmission of information relating to specific named cases.	5. The Centre shall not collect any data making it possible to identify individuals or small groups of individuals. It shall refrain from any transmission of information relating to specific named cases unless criminal offences have been committed.
Justification
It would be unacceptable for information of crucial importance for investigating a criminal offence to be available, but withheld.
Amendment 10 Article 2, point (a) (i)
(i) collecting, registering and analysing information, including data resulting from research, communicated by Member States as well as that emanating from Community, non-governmental national sources and competent international organizations; this collection, registration and analysis work shall also cover data on emerging trends in poly-drug use, including the combined use of licit and illicit psychoactive substances;	(i) collecting, registering and analysing information, including data resulting from research, communicated by Member States and non-Community European countries as well as that emanating from Community, non-governmental national sources and competent international organizations; this collection, registration and analysis work shall also cover data on emerging trends in poly-drug use, including the combined use of licit and illicit psychoactive substances, and on the illicit use of psychomodulation substances, providing information on and facilitating the exchange of "best practice" in the Member States;
Justification
Many drugs entering the European Union originate from neighbouring countries. The Centre should systematically collect and analyse data at least from those non-Community European countries, which take part in its work. Moreover, given the serious health consequences of the illicit and inappropriate use of psychomodulation substances, it is important that their use is also monitored by the Centre. The Centre should provide information and facilitate the exchange of "best practice" in the Member States.
Amendment 11 Article 2, point (b) (i)
(i) ensuring improved comparability, objectivity and reliability of data at European level by establishing indicators and common criteria of a non-binding nature, compliance with which may be recommended by the Centre, with a view to greater uniformity of the measurement methods used by the Member States and the Community; in particular, the Centre shall develop tools and instruments to facilitate Member States in the monitoring and evaluation of their national policies and the European Commission in monitoring and evaluation of Union policies;	(i) ensuring improved comparability, objectivity and reliability of data at European level by establishing indicators and common criteria, compliance with which may be recommended by the Centre, with a view to greater uniformity of the measurement methods used by the Member States and the Community; in particular, the Centre shall develop tools and instruments to assist Member States in the monitoring and evaluation of their national policies and the Commission in the monitoring and evaluation of Union policies; on the basis of collected data, the Centre shall also advise Member States on best practice.
Justification
Establishing common criteria and statistical methods for data collection are vitally important for the credibility of the work of the Centre. The Centre should advise Member States on best practice on the basis of the collected information.
Amendment 12 Article 2, point (b a) (new)
	(ba) Systematic evaluation of drug policies and consumption trends in order to facilitate policy-making and the dissemination of best practice
	(i) evaluating national drug policies and strategies, including legislation, on the basis of collected data and established indicators,
	(ii) evaluating consumption and supply trends.
Justification
The Centre should not only collect data but also evaluate it. This would facilitate policy-making both at the EU and the national level.
Amendment 13 Article 2, point (d) (ii a) (new)
	(iia) cooperating actively with Europol to attain maximum efficiency in monitoring the drugs problem;
Justification
Sharing information on drug use and drug-related crime would be beneficial for both EMCDDA and Europol.
Amendment 14 Article 2, point (d a) (new)
	(da) Information obligations The Centre shall be obliged, if it recognises new developments and changing trends, to inform the competent authorities of the Member States.
Justification
It must be clear that the Centre must operate proactively and flag up dangers on its own initiative.
Amendment 15 Article 9, paragraph 1, subparagraph 4
Each member of the management board may be assisted or represented by an alternative member. In the absence of the full member, who has the right to vote, the alternative member may exercise that right.	Each member of the management board may be represented by an alternate. In the absence of the full member, who has the right to vote, the alternate may exercise that right.
Justification
Clarification of the role of an alternate, as well as the wording.
Amendment 16 Article 9, paragraph 4
4. The management board shall adopt a three-year work programme on the basis of a draft submitted by the Centre's Director, after consulting the Scientific Committee and seeking the opinions of the Commission and shall forward it to the European Parliament, the Council and the Commission.	4. The management board shall adopt a three-year work programme on the basis of a draft submitted by the Centre's Director, after consulting the Scientific Committee and seeking the opinions of the Commission and the European Parliament, and shall forward it to the European Parliament, the Council and the Commission.
Justification
Amendment 17 Article 9, paragraph 6
6. In the case where the Commission expresses its disagreement with the three-year or annual work programme, these programmes shall be adopted by the Management Board by a 4/5 majority.	6. Where the Commission expresses its disagreement with the three-year or annual work programme, these programmes shall be adopted by the Management Board by a 3/4 majority.
Justification
The proposed threshold would give the Commission an unnecessarily strong say on the Centre's work.
Amendment 18 Article 10, paragraph 1
1. The Management Board shall be assisted by an Executive Committee. The Executive Committee shall be made up of the Chairperson and the Vice-Chairperson of the Management Board and two Commission representatives. The Director shall take part in its meetings, without voting rights.	1. The Management Board shall be assisted by an Executive Committee. The Executive Committee shall be made up of the Chairperson and the Vice-Chairperson of the Management Board, one of the independent experts designated by the European Parliament and one Commission representative. The Director shall take part in its meetings, without voting rights.
Justification
One of the independent experts designated by the European Parliament should be member in the Executive Committee, which has an important preparatory function. This solution would guarantee that the Parliament is properly informed about the work of the Centre. Moreover, it would be sufficient to have one Commission representative in this committee
Amendment 19 Article 11, paragraph 1
1. The Centre shall be headed by a Director appointed by the management board on a proposal from the Commission for a five-year period, which on a proposal from the Commission and after evaluation, may be extended once for a period of not more than five years.	1. The Centre shall be headed by a Director appointed by the management board on the basis of a list of candidates proposed by the Commission after an open competition, following the publication of a call for expression of interest in the Official Journal of the European Union and in one major newspaper in every Member State, for a five-year period, which on a proposal from the Commission and after evaluation by the management board, may be extended once for a period of not more than five years.
In the evaluation the Commission shall assess in particular:	In the evaluation the management board shall assess in particular:
- The results achieved in the first term of office and the way in which they were achieved;	- The results achieved in the first term of office and the way in which they were achieved;
- The Centre's duties and requirements in the coming years.	- The Centre's duties and requirements in the coming years.
	The evaluation shall be submitted without delay to the Commission and to the European Parliament.
Justification
This formulation has been used recently in several Regulations (the EMEA, the Centre for Disease Prevention and Control) establishing Community agencies. The application and selection procedure should be as transparent as possible to attract the attention of all potential candidates. The Management Board, as the appointing authority should carry out the evaluation of the work of the Director. The decision to extend the term of office of the Director should be taken only after that, if appropriate. As the evaluation concerns a holder of public office and a Community agency, it is important that it is made available to the Commission and the European Parliament
Amendment 20 Article 11, paragraph 2
2. Up on appointment to a first term, out of maximum two terms, the candidate nominated by the Management Board for the post of Director may be invited without delay to make a statement before the European Parliament and answer questions put by members of that institution.	2. Upon appointment to a first term, out of maximum two terms, the candidate nominated by the Management Board for the post of Director shall be invited without delay to make a statement before the European Parliament and answer questions put by members of that institution.
Justification
The appearance of the Director nominee before the Parliament before the final appointment should be made obligatory, as in the case of other decentralised agencies.
Amendment 21 Article 20, paragraph 2
Such cooperation should be based on working arrangements concluded with the aforementioned authorities and organisations. These arrangements shall be adopted by the Management Board on the basis of a draft submitted by the director and after the Commission has delivered an opinion. Where the Commission expresses its disagreement with these arrangements, the Management Board shall adopt them by a 4/5 majority.	Such cooperation should be based on working arrangements concluded with the aforementioned authorities and organisations. These arrangements shall be adopted by the Management Board on the basis of a draft submitted by the director and after the Commission has delivered an opinion. Where the Commission expresses its disagreement with these arrangements, the Management Board shall adopt them by a 3/4 majority.
Justification
The threshold for taking a decision if the Commission disagrees is unnecessarily high.
Amendment 22 Article 23, paragraph 1
The Commission shall initiate an external evaluation of the Centre every six years to coincide with the completion of two three-year work programmes of the Centre. This evaluation should also include the Reitox system. The Commission shall forward the evaluation report to the European Parliament, the Council and the Management Board.	The Commission shall initiate an external evaluation of the Centre every three years to coincide with the completion of each three-year work programme of the Centre. This evaluation should also include the Reitox system. The Commission shall forward the evaluation report to the European Parliament, the Council and the Management Board.
Justification
An evaluation cycle of six years is too long, as the operative environment of the Agency is rapidly evolving. It would be more appropriate to evaluate the work of the Centre more often, preferably during the last year of each work programme.
Amendment 23 Annex I, part A, paragraph 2, points 1 and 2
(1) monitoring the state of the drugs problem, in particular using epidemiological or other indicators, and monitoring emerging trends, in particular those involving poly-drug use;	(1) monitoring the state of the drugs problem, including the use of psychomodulation substances, and in particular using epidemiological or other indicators, and monitoring emerging trends, in particular those involving poly-drug use;
(2) monitoring the solutions applied to drug-related problems;	(2) monitoring the solutions applied to drug-related problems, providing information on and evaluating the measures in order to identify best practice and facilitate its exchange in the Member States;
Justification

The monitoring of the abuse of psychomodulation substances should belong to the tasks of the Centre. Also the evaluation of current drug policies should be one of the priority areas of the EMCDDA. It's not the task of the centre to evaluate the policies of the different member States. The Centre should nevertheless provide information and facilitate the exchange of "best practise" in the Member States.

PROCEDURE

Title	Proposal for a regulation of the European Parliament and of the Council on the European Monitoring Centre for Drugs and Drug Addiction
References	COM(2005)0399 – C6‑0256/2005 – 2005/0166(COD)
Committee responsible	LIBE
Opinion by   Date announced in plenary	ENVI 15.9.2005
Draftsman   Date appointed	Jiří Maštálka 22.9.2005
Previous draftsman
Discussed in committee	24..2006		22.2.2006
Date adopted	22.2.2006
Result of final vote	+: –: 0:	47 1 2
Members present for the final vote	Adamos Adamou, Georgs Andrejevs, Liam Aylward, Johannes Blokland, John Bowis, Frederika Brepoels, Hiltrud Breyer, Dorette Corbey, Avril Doyle, Jillian Evans, Anne Ferreira, Karl-Heinz Florenz, Milan Gaľa, Matthias Groote, Françoise Grossetête, Satu Hassi, Gyula Hegyi, Mary Honeyball, Marie Anne Isler Béguin, Caroline Jackson, Christa Klaß, Eija-Riitta Korhola, Holger Krahmer, Urszula Krupa, Aldis Kušķis, Marie-Noëlle Lienemann, Marios Matsakis, Roberto Musacchio, Miroslav Ouzký, Vittorio Prodi, Frédérique Ries, Karin Scheele, Carl Schlyter, Horst Schnellhardt, Richard Seeber, Jonas Sjöstedt, María Sornosa Martínez, Antonios Trakatellis, Evangelia Tzampazi, Thomas Ulmer, Anja Weisgerber, Åsa Westlund, Anders Wijkman
Substitute(s) present for the final vote	María del Pilar Ayuso González, Christofer Fjellner, Jutta D. Haug, Erna Hennicot-Schoepges, Jiří Maštálka, Miroslav Mikolášik, Renate Sommer
Substitute(s) under Rule 178(2) present for the final vote	Miguel Angel Martínez Martínez
Comments (available in one language only)

• [1]  OJ C ... /Not yet published in OJ.

PROĊEDURA

Title		Proposal for a regulation of the European Parliament and of the Council on the European Monitoring Centre for Drugs and Drug Addiction
References		COM(2005)0399 – C6-0256/2005 – 2005/0166(COD)
Date submitted to Parliament		31.8.2005
Committee responsible   Date announced in plenary		LIBE 6.9.2005
Committee(s) asked for opinion(s)   Date announced in plenary		JURI 6.9.2005		ENVI 6.9.2005
Not delivering opinion(s)   Date of decision		JURI 24.10.2005
Enhanced cooperation   Date announced in plenary
Rapporteur(s)   Date appointed		Frederika Brepoels 14.9.2005
Previous rapporteur(s)
Simplified procedure – date of decision
Legal basis disputed   Date of JURI opinion
Financial endowment amended   Date of BUDG opinion
European Economic and Social Committee consulted – date of decision in plenary
Committee of the Regions consulted – date of decision in plenary
Discussed in committee		23.11.2005	21.2.2006		21.3.2006
Date adopted		21.3.2006
Result of final vote	+ – 0	43 0 0
Members present for the final vote		Alexander Nuno Alvaro, Roberta Angelilli, Edit Bauer, Johannes Blokland, Mihael Brejc, Kathalijne Maria Buitenweg, Maria Carlshamre, Giusto Catania, Jean-Marie Cavada, Carlos Coelho, Agustín Díaz de Mera García Consuegra, Kinga Gál, Patrick Gaubert, Elly de Groen-Kouwenhoven, Lilli Gruber, Lívia Járóka, Timothy Kirkhope, Ewa Klamt, Magda Kósáné Kovács, Barbara Kudrycka, Stavros Lambrinidis, Romano Maria La Russa, Edith Mastenbroek, Claude Moraes, Hartmut Nassauer, Martine Roure, Inger Segelström, Ioannis Varvitsiotis, Manfred Weber, Stefano Zappalà, Tatjana Ždanoka
Substitute(s) present for the final vote		Frederika Brepoels, Richard Corbett, Gérard Deprez, Lutz Goepel, Ignasi Guardans Cambó, Sylvia-Yvonne Kaufmann, Antonio Masip Hidalgo, Hubert Pirker, Herbert Reul, Marie-Line Reynaud, Rainer Wieland
Substitute(s) under Rule 178(2) present for the final vote		Pierre Schapira
Date tabled		3.4.2006
Comments (available in one language only)		...